# Effect of rIL-21 on Metastases in Lymph Nodes in Melanoma Skin Cancer

> **NCT00601861** · PHASE2 · TERMINATED · sponsor: **Novo Nordisk A/S** · enrollment: 1 (actual)

## Conditions studied

- Cancer
- Malignant Melanoma

## Interventions

- **DRUG:** recombinant interleukin-21

## Key facts

- **NCT ID:** NCT00601861
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-02-13
- **Primary completion:** 2008-06-25
- **Final completion:** 2008-06-25
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** See termination reason in detailed description
- **Last updated:** 2017-03-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00601861

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00601861, "Effect of rIL-21 on Metastases in Lymph Nodes in Melanoma Skin Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00601861. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*